Abstract: The subject invention provides therapeutic compositions and uses thereof for improving pulmonary function. In one embodiment, the therapeutic composition comprises one or more free amino acids selected from lysine, glycine, threonine, valine, tyrosine, aspartic acid, isoleucine, tryptophan, asparagine, and serine; and electrolytes. In one embodiment, the subject invention can be used to prevent or treat long-term lung complications induced by radiation.
Type:
Grant
Filed:
March 11, 2014
Date of Patent:
July 16, 2019
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
Type:
Grant
Filed:
February 1, 2018
Date of Patent:
June 25, 2019
Assignee:
Bristol-Myers Squibb Company
Inventors:
Qingjie Liu, Scott Hunter Watterson, John E. Macor, Khehyong Ngu, Saleem Ahmad
Abstract: A composition for delivery of a hydrophobic bioactive agent is provided that provides for a partially solubilized storage solution that upon exposure to the air results in a fully solubilized bioactive agent in a molecular form for optimal delivery to the skin of a subject. The composition is used for the therapeutic treatment or diagnosis of numerous skin conditions such as inflammation, and epidermal or musculoskeletal pain.
Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
June 4, 2019
Assignee:
PanOptica, Inc.
Inventors:
David P. Bingaman, Paul G. Chaney, Martin B. Wax
Abstract: In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided.
Type:
Grant
Filed:
August 29, 2014
Date of Patent:
June 4, 2019
Assignees:
The Wistar Institute of Anatomy and Biology, Drexel University
Inventors:
Paul M. Lieberman, Nadezhda Tikhmyanova-Eckert, Joseph M. Salvino
Abstract: Provided is a pharmaceutical formulation and a method associated therewith for treating inflammation. The pharmaceutical formulation includes therapeutically effective amounts of sesquiterpenes such as ?-caryophyllene and two flavonoids. The two flavonoids include baicalin and catechin.
Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.
Type:
Grant
Filed:
May 12, 2016
Date of Patent:
May 7, 2019
Assignee:
ALFASIGMA S.P.A.
Inventors:
Paola Maffei, Milena Bachetti, Giuseppe Bottoni, Giuseppe Claudio Viscomi
Abstract: The present disclosure relates to a method for inducing pluripotent stem cells by inducing reprogramming and/or dedifferentiation of differentiated adult cells using shikimic acid, a plant extract or plant stem cells containing shikimic acid and an extract of dedifferentiated stem cells (callus), pluripotent stem cells prepared by the method and a composition containing the pluripotent stem cells. In accordance with the present disclosure, ethical concerns implicated with the use of eggs to prepare pluripotent stem cells such as embryonic stem cell can be resolved. And, because the plant stem cell extract unharmful to human is used, pluripotent stem cells with proven safety can be prepared and they may be used to develop immunocompatible cell therapy agents suited for individuals. In addition, by pluripotent stem cells from individuals having diseases, the present disclosure will be very useful in studying the cause of diseases and devolving therapeutic strategy.
Type:
Grant
Filed:
December 13, 2016
Date of Patent:
April 9, 2019
Assignees:
AMOREPACIFIC CORPORATION, SNU R&DB FOUNDATION
Inventors:
Ah Reum Kim, Su Na Kim, Won Seok Park, Yoo Wook Kwon, Young Bae Park, Hyo Soo Kim, Jae Seung Paek
Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.
Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
Type:
Grant
Filed:
June 16, 2011
Date of Patent:
January 1, 2019
Assignees:
Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd., Aristotle University of Thessaloniki
Inventors:
Elliot Berry, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis
Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
Type:
Grant
Filed:
January 19, 2017
Date of Patent:
December 11, 2018
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Abstract: The presently described technology provides compositions comprising aryl carboxylic acids and, for example NSAIDs, chemically conjugated to oxycodone (4,5-?-epoxy-14-hydroxy-17-methylmorphinan-6-one) to form novel prodrugs/compositions of oxycodone, including benzoates, salicylates, propionates, fenamates, and acetates, which have a decreased potential for abuse of oxycodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
Type:
Grant
Filed:
November 14, 2017
Date of Patent:
December 4, 2018
Assignee:
KemPharm, Inc.
Inventors:
Travis Mickle, Sven Guenther, Sanjib Bera, Bindu Bera, Jaroslaw Kanski, Andrea Martin
Abstract: The present invention is a composition and method of treatment for skin disorders, conditions, and severe skin dryness in general through topical systematic and periodic application of a formulation that generally may include salicylic acid, glycolic acid, urea, dimethyl isosorbide, ethoxydiglycol, barrier repair agents, anti-irritants, humectants, and also has an acidic pH formulation.
Abstract: The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer.
Type:
Grant
Filed:
July 28, 2016
Date of Patent:
November 13, 2018
Assignee:
INSTITUT GUSTAVE ROUSSY
Inventors:
Angelo Paci, Thierry Martens, Michael Rivard, Patrick Couvreur, Didier Desmaele, Joachim Caron
Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
October 9, 2018
Assignee:
PanOptica, Inc.
Inventors:
David P. Bingaman, Paul G. Chaney, Martin B. Wax
Abstract: The present invention relates to a natural lubricant for direct compression and a method of preparing a synthetic additive-free natural tablet using the same. More particularly, the invention provides a crude fat-containing bean powder, which is used as a natural lubricant, and a method of preparing a natural tablet using the bean powder by a dry granulation process which is carried out using a roller compactor.
Type:
Grant
Filed:
October 26, 2017
Date of Patent:
October 2, 2018
Assignee:
CJ Cheiljedang Corporation
Inventors:
Sung Ki Kim, Jae Seok Shim, Sang Hyeon Kim
Abstract: Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective ?-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization.
Type:
Grant
Filed:
February 8, 2017
Date of Patent:
September 4, 2018
Assignees:
University of Washington, PhaseRx, Inc.
Inventors:
Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Scott M. Henry, Robert W. Overell, Paul H. Johnson
Abstract: Provided herein are deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams, pharmaceutical compositions thereof and methods of treating infectious disease with deuterated compounds or pharmaceutical compositions thereof.
Abstract: Disclosed are compositions and methods for treating a disease, such as infection, pain, or inflammation, by using the compositions. Particularly, disclosed is a method of treating oral pain, wherein, the above-described compositions are applied to the oral mucosa; the compositions undergo in-situ gelation, optimal adhesion to the oral mucosa, controlled erosion and controlled release of the active ingredient, i.e., benzocaine, which provides a superior degree of pain relief or analgesia for an extended period of time.
Type:
Grant
Filed:
June 2, 2011
Date of Patent:
August 7, 2018
Assignee:
TRILOGIC PHARMA LLC
Inventors:
Hemant H. Alur, James A. H. Harwick, Mondal Pravakar, Thomas P. Johnston